A Penile Sore or Growth That Persists: HPV and Penile Cancer
A sore on the penis does not look like cancer. It looks like an infection, so the first prescription is usually an antibiotic. A month later it is still there, so it looks like a reaction, and the next prescription is a cream. Pain is often absent early, which removes the one thing that makes a man insist. The months that pass are the part that matters most. Healz holds that whole stretch of months as one case instead of three unrelated visits.
This post stays clinical and plain, because embarrassment is this disease's main ally and vague writing feeds it.
Why a cancer on the outside of the body is still found late
Penile cancer is uncommon where healthcare is well resourced. The NCI PDQ health professional summary on penile cancer treatment calls it rare in most developed nations and puts the United States rate under 1 per 100,000 men per year. The EAU-ASCO penile cancer guideline, 2026 edition, gives about 0.94 per 100,000 in Europe, with rising trends in several European countries.
Rarity explains why a clinician does not reach for it first. It does not explain the delay, because the lesion is visible from the day it starts. A single-centre study of 48 men treated between 2010 and 2024 found a median of 12.4 months from first presentation to arrival at a tertiary centre, and surgery after 12 months was associated with higher recurrence risk and lower two-year recurrence-free survival (Negri et al., World Journal of Urology, 2026).
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
The delay has two halves and both are human. Cancer Research UK puts the first plainly: it is not unusual to feel embarrassed or frightened by such symptoms. The second is empirical treatment, reasonable once and a problem when repeated, because a foul-smelling discharge is usually caused by infection or irritation and cancer is a much less common cause (Cancer Research UK). The first antibiotic is good medicine. The third is a missing biopsy.
Two routes to the same diagnosis: HPV and chronic inflammation
More than 95% of penile cancers are squamous cell carcinoma, and they arrive by two routes (EAU-ASCO). One runs through human papillomavirus. The other does not, and is associated instead with chronic inflammation of the glans and foreskin, including lichen sclerosus.
The precursor for both is penile intraepithelial neoplasia, or PeIN, which the current classification splits the same way the invasive tumours are split, into HPV-associated and HPV-independent (differentiated) forms (EAU-ASCO).
The WHO 2022 classification uses the presence of HPV as a key determinant for broadly classifying penile squamous cell carcinoma, which is why a modern pathology report separates the two (EAU-ASCO). The HPV-associated group includes the basaloid and warty subtypes; the HPV-independent group includes the usual type along with verrucous and sarcomatoid subtypes. On prognosis the guideline is careful: HPV status alone has shown inconsistent prognostic value, while p16 immunohistochemistry has been reported as an independent prognostic marker that outperforms it.
The risk list carries unequal weight. EAU-ASCO names HPV infection as the main risk factor, then phimosis and chronic penile inflammation, lichen sclerosus, smoking, ultraviolet A phototherapy with psoralen (PUVA), low socioeconomic status or education, and lack of neonatal circumcision, noting that circumcision reduces invasive cancer risk but does not appear to reduce PeIN risk. The same virus drives cancers at other sites, and the pattern of a lesion dismissed for months repeats there: see our pieces on anal cancer and HPV symptoms and on HPV-related throat cancer.
What the lesion looks like, and what it fails to do
Cancer Research UK lists the symptoms as a growth or sore on the penis, bleeding or a foul-smelling discharge, a rash, difficulty pulling back the foreskin, a change in colour of the penis or foreskin, swelling or irritation in the head, and thickening of the skin. A growth or sore that does not heal within 4 weeks can be a symptom of penile cancer, it may look like a wart, an ulcer or a blister, and it might not be painful.
That last clause does most of the damage, because no alarm signal is attached. EAU-ASCO adds that the appearance is heterogeneous, that these tumours often present as raised or ulcerous lesions which can be locally destructive, and that one can be hidden under the foreskin in phimosis. A lesion nobody can see is a lesion nobody dates.
Why a biopsy, and not an appearance, makes the diagnosis
The guideline position is that a biopsy should be obtained when there is doubt about the exact nature of the lesion. A pretreatment biopsy is recommended when malignancy is not clinically obvious, or when non-surgical treatment such as topical agents, laser or radiotherapy is planned, and it is useful even in obvious cases because it guides decisions such as surgical staging (EAU-ASCO).
What comes back is why people search for how to read a pathology report. The words that steer everything after it are the subtype, the grade, the depth and whether the corpora are involved, lymphovascular or perineural invasion, the margin, and the HPV or p16 result. They sort the tumour into a risk group, and the risk group decides whether the groin is staged surgically.
Imaging has a narrower job than most people expect. MRI does not outperform physical examination at separating T1 from T2 disease; it is useful where corporal invasion is uncertain and organ-sparing surgery is being considered, and ultrasound is the alternative where MRI is unavailable (EAU-ASCO).
The groin decides the outcome
Every assessment includes both groins. EAU-ASCO makes examination of both groins a strong recommendation, with the number, laterality and characteristics of any suspicious nodes recorded. Nodal status is the most important prognostic factor in penile cancer, and the NCI PDQ health professional summary states that curability decreases sharply for stage III and stage IV disease, stage III being defined by nodal involvement.
That produces the rule which surprises people most. In a man whose groins feel normal, surgical staging is recommended from T1b upward, because routine imaging is not recommended in clinically node-negative patients: CT, MRI, ultrasound and PET/CT cannot reliably detect micrometastases (EAU-ASCO). Dynamic sentinel node biopsy is the preferred method, with inguinal ultrasound and fine-needle aspiration of abnormal nodes beforehand. The risk groups are explicit and there are three. Low risk is well-differentiated (G1) pTa, pTis and pT1 without lymphovascular or perineural invasion, where the metastasis risk is too low to justify surgical staging. Intermediate risk is a moderately differentiated (G2) pT1a tumour, carrying a 6% to 8% chance of micrometastatic nodal disease, where the guideline says surveillance can be discussed as an alternative. High risk is pT1 with that invasion or poor differentiation, plus all pT2 to pT4 tumours, where the risk reaches 22% to 30% in pT1b G2 disease and staging is recommended.
A palpable node is not automatically cancer: inguinal adenopathy is common here and may result from infection. Older guidance, still in the NCI PDQ health professional summary, waits 3 or more weeks after the primary lesion is out and a course of antibiotics is finished before dissecting. The 2026 EAU-ASCO guideline has moved away from that step, stating that using antibiotics to resolve enlarged nodes may delay staging and treatment and is not recommended, and requiring an image-guided biopsy to confirm nodal metastasis before any treatment, with pelvic staging by FDG-PET/CT or CT where nodes are involved.
What treatment is trying to preserve
These options are named, not ranked, because which applies depends on the pathology and the nodes. For biopsy-confirmed PeIN, EAU-ASCO offers topical 5-fluorouracil or imiquimod, and states that failed topical treatment should not be repeated. Laser ablation with carbon dioxide or Nd:YAG laser is offered for PeIN, Ta and T1 lesions. Organ-sparing surgery, covering circumcision, wide local excision, glans resurfacing and glansectomy, is a strong recommendation for lesions confined to the glans and prepuce in men who will comply with strict follow-up, and radiotherapy for selected T1 or T2 lesions.
Further up the stages the operations get larger: partial penectomy where the corpora cavernosa are invaded, total penectomy with perineal urethrostomy for tumours not amenable to partial amputation. For the nodes, inguinal lymphadenectomy is matched to cN stage, neoadjuvant cisplatin-based and taxane-based chemotherapy is offered for bulky or pelvic nodal disease, and adjuvant radiotherapy for pN2 and pN3 disease. Almost every organ-sparing option sits at the early end, and what moves a case off that end is time.
Prevention sits at the other end. The NCI lists penile cancer among the six cancers HPV causes, and states that HPV vaccination is recommended at age 11 or 12, can start at age 9, and is recommended regardless of sex.
How Healz holds one lesion's whole timeline in one place
The dates the lesion first appeared, the creams and antibiotics already tried, and the biopsy wording belong in one case. Healz keeps them in one chat rather than ten apps: the dated photographs, what was prescribed and when it stopped working, the pathology report, the groin findings and the imaging.
Frontier AI works that case in the one place it sits. Healz is equipped with root-cause technology, so it does not stop at the first label: it asks what a rushed appointment skipped, cross-checks the case against more than a million rare cases, and reads the pathology report for the details that decide the next step, the subtype, the grade, the depth, the lymphovascular invasion, the margin and the p16 result. Healz's memory pulls the medical facts out of every upload, dates them and keeps the abnormal values up front, so a lesion first photographed in March is still dated March when a biopsy report lands in September. The same chat searches current studies and trials, and produces documents such as a PDF of questions for the next appointment. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Can a sore on the penis that will not heal be cancer?
It can be, which is why the four-week mark matters. Cancer Research UK states that a growth or sore on the penis that does not heal within 4 weeks can be a symptom of penile cancer, that it may look like a wart, an ulcer or a blister, and that it might not be painful. Most prove to be something else, which is why a persistent one is worth a definite answer rather than a third prescription.
- How is penile cancer diagnosed?
By biopsy, not by looking. EAU-ASCO states that a biopsy should be obtained when there is doubt about the exact nature of the lesion, and recommends a pretreatment biopsy when malignancy is not clinically obvious or when topical, laser or radiotherapy treatment is planned. Imaging supports that biopsy rather than replacing it.
- Does HPV cause penile cancer, and does the HPV vaccine prevent it?
HPV causes a substantial share, though estimates differ: EAU-ASCO attributes roughly a third to a half of cases to HPV-associated carcinogenesis, while the NCI states 63%. The NCI lists penile cancer among the six cancers HPV causes and states that vaccination is recommended at age 11 or 12, can begin at age 9, and is recommended regardless of sex. An HPV-independent route through chronic inflammation also exists, so vaccination does not remove the reason to take a persistent lesion seriously.
- Why would the groin be operated on if the lymph nodes feel normal?
Because micrometastases do not show up on scans. EAU-ASCO recommends surgical staging for patients at high risk of them, meaning T1b or higher, and notes that CT, MRI, ultrasound and PET/CT cannot reliably detect them.
A sore that does not heal is not embarrassing information, it is dated information, and the months it spends being treated as something else are the part of this disease anyone can still change.
Written by Healz Team · Filed under Health Insights
